Page 1

AddLife Interim Report 1 January - 31 March 2021 Record quarter with strong organic growth in Labtech 1 JANUARY - 31 MARCH 2021 ( 3 MONTHS ) ⚫ Net sales increased by 65 percent to SEK 1,736m ( 1,053 ) , of which organic growth amounted to 54 percent and acquired growth amounted to 17 percent . ⚫ EBITA increased by 209 percent to SEK 326m ( 106 ) , corresponding to an EBITA- margin of 18.8 percent ( 10.0 ) . ⚫ Profit after tax increased by 318 percent to SEK 226m ( 54 ) . ⚫ Earnings per share amounted to SEK 2.01 ( 0.48 ) . Earnings per share for the last 12 months amounted to SEK 6.16 ( 4.63 ) . • Cash flow from operating activities amounted to SEK 184m ( 80 ) . The equity ratio was 48 percent ( 46 ) . ⚫ Return on working capital ( P / WC ) amounted to 122 percent ( 103 ) . • Two acquisitions were completed after the end of the reporting period , Vision Ophthalmology Group and Helathcare 21. The acquisitions are expected to add annual net sales of SEK 2,400m and EBITA of approximately SEK 310m . The acquisitions have been financed through new credits of SEK 2,250m and new share issue of 7,951,958 Class B - shares . SEKM Net sales EBITA EBITA - margin , % 3 months ending 31 - Mar - 21 31 - Mar - 20 change 1,053 65 % 106 209 % 209 % EBITA GROWTH Q1 2021 122 % P / WC Q1 2021 12 months ending 31 - Mar - 21 31 - Dec - 20 1,736 5,956 5,273 326 1,022 802 18.8 % 10.0 % 17.2 % 15.2 % Profit before tax 287 69 313 % 877 659 Profit for the period 226 54 318 % 692 520 Earnings per share before dilution , SEK 2.01 0.48 319 % 6.16 4.63 Earnings per share after dilution , SEK 2.00 0.48 317 % 6.14 4.61 1